AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
Following a recent U-turn from the US Food and Drug Administration (FDA), the regulatory path ahead for UniQure’s Huntington’s disease…
29 Jul 2026
GSK eyes future growth with cost-cutting plan amid promising Q2
Amid a Q2 results debut, GSK has also announced a new cost-cutting and UK R&D strategy as recently appointed CEO, Luke Miels, looks to balance the impact of key drug…
29 Jul 2026
FDA grants fast track designation for HAYA Therapeutics’ HTX-001
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). Targeting long non-coding…
29 Jul 2026
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes. The deal grants CORE Biomedicine rights to develop and commercialise a portfolio…
28 Jul 2026
Leadership changes afoot at two CGT biotechs
Cell therapy specialist Legend Biotech has announced the abrupt departure of its CEO, while Sarepta has revealed its new leader after a long-planned transition, marking two contrasting approaches at the…
28 Jul 2026
Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development
Apnimed is eyeing a spot on the Nasdaq exchange through an IPO worth up to $160m, which will support the company as it looks to debut its potentially “best-in-class” therapy…
28 Jul 2026
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome. ReNU syndrome is…